Literature DB >> 9098552

6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates.

S Jordan1, J L Eberling, K S Bankiewicz, D Rosenberg, P G Coxson, H F VanBrocklin, J P O'Neil, M E Emborg, W J Jagust.   

Abstract

The tracer 6-[18F]fluoro-L-m-tyrosine (FMT) was studied with regard to its biochemistry and kinetics, as well as its utility in evaluating brain dopaminergic function in primates before and after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment using positron emission tomography (PET). Plasma analysis of FMT and its F18-labeled metabolites 6-fluoro-3-hydroxyphenylacetic acid (FPAC) and 6-fluoro-3-hydroxyphenylethylamine (FMA) during PET scanning enabled kinetic analysis of FMT uptake. A separate study examined brain FMT metabolism in MPTP-naive monkeys euthanized 60 or 120 min after FMT injection. Almost 60% of total plasma F-18 activity was associated with FPAC and FMA 120 min after FMT injection. The FMT signal accumulated preferentially in dopaminergic areas such as caudate and putamen. This bilateral FMT signal was disrupted after unilateral intracarotid artery (ICA) MPTP infusion which reduced ipsilateral striatal activity. A three compartment three kinetic rate constant model for FMT uptake revealed reduced FMT decarboxylation (k3) in ipsilateral caudate and putamen after unilateral MPTP although a further decrease was not evident after intravenous MPTP. FPAC was the major F-18 species in all brain regions except in cerebellum where FMT was predominant 60 min post-mortem. FPAC was most concentrated in dopaminergic areas whereas lower levels occurred in areas containing few dopamine terminals. These data demonstrate preferential FMT metabolism and F-18 retention in dopaminergic tissue and support the use of FMT to evaluate normal and abnormal dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098552     DOI: 10.1016/s0006-8993(96)01366-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Dopamine and frontostriatal networks in cognitive aging.

Authors:  Ellen C Klostermann; Meredith N Braskie; Susan M Landau; James P O'Neil; William J Jagust
Journal:  Neurobiol Aging       Date:  2011-04-20       Impact factor: 4.673

2.  An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism.

Authors:  S Jordan; K S Bankiewicz; J L Eberling; H F VanBrocklin; J P O'Neil; W J Jagust
Journal:  Neurochem Res       Date:  1998-04       Impact factor: 3.996

3.  A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Authors:  John R Forsayeth; Jamie L Eberling; Laura M Sanftner; Zhu Zhen; Philip Pivirotto; John Bringas; Janet Cunningham; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2006-06-16       Impact factor: 11.454

4.  Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.

Authors:  Krystof S Bankiewicz; Marcel Daadi; Philip Pivirotto; John Bringas; Laura Sanftner; Janet Cunningham; John R Forsayeth; Jamie L Eberling
Journal:  Exp Neurol       Date:  2005-12-09       Impact factor: 5.330

5.  Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults.

Authors:  Christopher T Smith; Deanna L Wallace; Linh C Dang; Esther Aarts; William J Jagust; Mark D'Esposito; Charlotte A Boettiger
Journal:  J Neurophysiol       Date:  2015-12-16       Impact factor: 2.714

6.  Dopamine and the cognitive downside of a promised bonus.

Authors:  Esther Aarts; Deanna L Wallace; Linh C Dang; William J Jagust; Roshan Cools; Mark D'Esposito
Journal:  Psychol Sci       Date:  2014-02-13

7.  Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques.

Authors:  Takuya Hayashi; Shohei Wakao; Masaaki Kitada; Takayuki Ose; Hiroshi Watabe; Yasumasa Kuroda; Kanae Mitsunaga; Dai Matsuse; Taeko Shigemoto; Akihito Ito; Hironobu Ikeda; Hidenao Fukuyama; Hirotaka Onoe; Yasuhiko Tabata; Mari Dezawa
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

8.  Relationship of striatal dopamine synthesis capacity to age and cognition.

Authors:  Meredith N Braskie; Claire E Wilcox; Susan M Landau; James P O'Neil; Suzanne L Baker; Cindee M Madison; Jennifer T Kluth; William J Jagust
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

9.  Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.

Authors:  Louisa C Johnston; Jamie Eberling; Philip Pivirotto; Piotr Hadaczek; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

10.  PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models.

Authors:  Ronald L Klein; Robert D Dayton; Tracee L Terry; Chris Vascoe; John J Sunderland; Kerrie H Tainter
Journal:  Brain Res       Date:  2009-02-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.